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Background: A humanitarian emergency involves a complete breakdown of authority that often disrupts routine
health care delivery, including immunization. Diarrheal diseases are a principal cause of morbidity and mortality
among children during humanitarian emergencies. The objective of this study was to assess if vaccination against
rotavirus, the most common cause of severe diarrhea among children, either as an addition to routine
immunization program (RI) or supplemental immunization activity (SIA) would be cost-effective during a humanitarian
emergency to decrease diarrhea morbidity and mortality, using Somalia as a case study.
Methods: An impact and cost-effectiveness analysis was performed comparing no vaccine; two-dose rotavirus SIA and
two-dose of RI for the 424,592 births in the 2012 Somali cohort. The main summary measure was the incremental cost
per disability-adjusted life-year (DALY) averted. Univariate sensitivity analysis examined the extent to which the
uncertainty in the variables affected estimates.
Results: If introduced in Somalia, a full-series rotavirus RI and SIA would save 908 and 359 lives, respectively,
and save US$63,793 and US$25,246 in direct medical costs, respectively. The cost of a RI strategy would be US
$309,458. Because of the high operational costs, a SIA strategy would cost US$715,713. US$5.30 per DALY would
be averted for RI and US$37.62 per DALY averted for SIA. Variables that most substantially influenced the cost-effectiveness
for both RI and SIA were vaccine program costs, mortality rate, and vaccine effectiveness against death.
Conclusions: Based on our model, rotavirus vaccination appears to be a cost-effective intervention as either RI or
SIA, as defined by the World Health Organization as one to three times the per capita Gross Domestic Product
(Somalia $112 in 2011). RI would have greater health impact and is more cost effective than SIA, assuming feasibility
of reaching the target population. However, given the lack of infrastructure, whether RI is realistic in this setting remains
unanswered, and alternative approaches like SIA should be further examined.
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A complex humanitarian emergency involves a breakdown
of authority that goes beyond the mandate or response
capacity of any single country or United Nations agency
[1]. This leads to the creation of refugees (those who leave
their country of origin) and internally displaced persons* Correspondence: lisa.gargano@gmail.com
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unless otherwise stated.(IDPs) (those who are displaced but remain in their
country). At the end of 2012, there were 45.2 million
people worldwide forcibly displaced due to conflict
and persecution [2]. On average, 13% of all persons of
concern (refugees, IDPs, stateless persons, and those
recently returned home) were children under the age
of five years [2]. Humanitarian emergencies, regardless
of timing, have a number of common risk factors for
communicable diseases including mass population move-
ment and resettlement in temporary locations, overcrowdingl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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degradation, impoverishment, scarcity of safe water, poor
sanitation and waste management, poor nutritional status as
a result of food shortages, and poor access to health care.
These risk factors are inextricably linked to excess risk of
morbidity and mortality from waterborne and vaccine
preventable diseases, the reduction of which is the aim of
public health interventions during crises. These emergencies
can be sudden or of a more protracted with a longer term
effect as it currently being seen in Somalia and Syria, both of
which are seeing ongoing insecurity, continued displacement
of people, and lack of sound governance impacting the
population’s health and wellbeing.
Infectious diseases continue to cause high levels of
morbidity and mortality during a humanitarian emer-
gency. Measles in children has been shown repeatedly to
be a major, and often the most important, cause of death
among refugee and displaced children [3]. However
through supplemental immunization campaigns, mortal-
ity from this cause has been greatly reduced [3]. Today,
diarrheal diseases are a principal cause of morbidity and
mortality in humanitarian emergencies [4].
Worldwide, rotavirus is the most common cause of se-
vere diarrhea among infants and young children [5,6].
Where appropriate resources are available, rotavirus is
usually an easily managed disease of childhood, but glo-
bally the World Health Organization (WHO) estimates
that 453,000 children under the age of five years died of
rotavirus in 2008 [7,8] and almost two million more be-
come severely ill [9]. In developing countries, the major-
ity of severe rotavirus disease occurs during the first
year of life [10].
In 2006, two vaccines against rotavirus infection were
shown to be safe and effective in children: two-dose
Rotarix by GlaxoSmithKline™ and three-dose RotaTeq by
Merck™ [11,12]. Both are administered orally and con-
tain attenuated live virus [13]. As of January 2014, 53
countries have introduced rotavirus vaccines through their
national immunization programs, including 20 low-income
countries eligible for vaccine introduction support from
Gavi, the Vaccine Alliance (formerly the Global Alliance
for Vaccines and Immunizations) [14]. The incidence and
severity of rotavirus infections has declined significantly in
countries that have acted on WHO recommendations
and introduced the rotavirus vaccine into their routine
immunization programs [15]. In 2013, WHO published
a position paper recommending the use of rotavirus
vaccines in all national immunization programs, particu-
larly in south and south-eastern Asia and sub-Saharan
Africa [16]. Somalia has not introduced rotavirus vac-
cination into its routine immunization program.
A 1991 military coup in Somalia, followed by years of
civil war, devastated much of the country’s infrastructure,
including its healthcare system [17]. Multiple attempts torestore a stable national government have failed and much
of Somalia remains in protracted conflict, with large popu-
lations of IDPs having inadequate access to health and so-
cial services, especially in the two southern zones [18]. In
2012, Somalia was the second largest country of origin for
refugees, with more than 1.1 million people fleeing due to
conflict, violence, drought, and famine [2]. Indicators of
the collapse of the health system include child and mater-
nal mortality rates that rank among the highest globally
[19] and record low levels of routine child immunization
coverage, which have remained at these levels for the past
20 years [20], from 19% three-dose diphtheria, tetanus,
and pertussis (DTP3) coverage in 1997 to 34% in 2013
[21,22]. Somalia’s routine immunization services are heav-
ily supported by UNICEF and partner agencies. However,
security problems and inadequate resources hamper cover-
age of these services [23]. As a result, much vaccination is
accomplished through supplemental immunization activ-
ities (SIAs), each occurring over a few-day period at the re-
gional level and larger areas [24].
An analysis of the cost-effectiveness of rotavirus vaccine
found that in 68 of the 72 (94%) Gavi-eligible countries
the vaccine was considered cost-effective [25]. Although
studies exist, specifically with new vaccines, there have
been no analysis published during a humanitarian emer-
gency using a SIA, despite the establishment of the
WHO/ Strategic Advisory Group of Experts (SAGE) on
Immunization framework for decision-making of vaccin-
ation in acute humanitarian emergencies [26].
The objective of this study was to determine the po-
tential health impact and cost-effectiveness of adding
rotavirus vaccine to the routine immunization program
(RI) and of a national supplemental rotavirus vaccination
campaign in Somalia, a country that has experienced a
protracted humanitarian emergency. This analysis was
conducted from the publicly funded healthcare system
perspective to aid governments and donor organizations
in decisions about whether to introduce rotavirus vac-
cination during a humanitarian emergency.
Methods
Overview of model
Disease-specific, decision-tree models were developed to
estimate the impact and cost-effectiveness of rotavirus
vaccination in both a national routine vaccination pro-
gram and a national supplemental rotavirus immunization
activity (SIA) by comparing the cost and burden of disease
with and without such administration. We examined
Rotarix since it requires fewer total doses (2 versus 3 for
RotaTeq) and may be more amenable to use in emer-
gency. The model was created for use in Somalia and
estimated health outcomes and direct medical costs as-
sociated with rotavirus disease for the 2012 Somalia
annual birth cohort of 424,594 infants followed for one
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50% of the birth cohort would be eligible to receive
two-doses of the vaccine given in a hypothetical 26-week
dosing window (between 6 and 32 weeks of age). We also
adjusted for those children who would have died from
rotavirus disease before vaccination occurred among those
receiving SIA by calculating that 38% of deaths would
have occurred prior to vaccination, leaving 62% of deaths
potentially prevented during the 26-week age window as-
suming equal age distribution in the vaccine eligible win-
dow [28]. For RI, we assumed rotavirus vaccine would be
given at the recommended ages (6 and 10 weeks) for the
first two doses of vaccines in the routine immunization
program. Variables considered in the analysis are listed in
Table 1. The model inputs include diarrhea and rotavirusTable 1 Principle base-case values, sensitivity ranges, and ref
of a rotavirus vaccination campaign in Somalia
Parameter Base-case estim
Epidemiologic
2012 Birth cohort 424,594
Diarrhea disease 2-week incidence, % 21
Diarrhea cases, severea, % 6
Diarrhea cases, moderatea, % 42
Diarrhea cases, milda, % 52
Rotavirus incidence severeb, % 48
Rotavirus incidence moderatec, % 35
Rotavirus incidence mild/subclinicald, % 17
Receive care, % 25
Mortality associated with Rotavirus (per 1,000) 9.1
Clinical
Proportion eligible for vaccination at SIA, % 50
SIA coverage, % 60






Length of hospital stay severe, days 4
Length of hospital stay moderate, days 2
Economic, US$
Gavi price per dose 0.15
SIA operational cost per child 3.00
RI operational costs per child 0.34
Cost per day of care 1.01
aof all diarrhea.
bof severe diarrhea cases.
cof moderate diarrhea cases.
dof mild diarrhea cases.incidence; vaccine coverage, effectiveness, and cost (ad-
ministrative and price of vaccine); medical care service
costs and proportion utilizing services; and mortality rate.
We did not consider direct non-medical costs, such as
transportation costs or indirect costs, such as time lost to
parents. We chose to estimate the burden of disease dur-
ing the first year of life instead of during the first five years
because of the mobility of the population and because in
other African countries, over 82% of rotavirus infections
occur among children under one year of age [29].
Model inputs
Disease burden
UNICEF’s Somalia multiple indicator cluster survey 3
(MICS3) conducted in 2005–2006 estimated the two-weekerences for model inputs for estimating cost-effectiveness
ate Sensitivity range References
NA [27]








4.55-13.65 (+/− 50%) [29,33]
NA Assumption
45-75 (+/−25%) [34-37]
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21% [30]. We determined rates of severe, moderate, and
mild all-cause diarrhea among children less than 5 years of
age from published estimates [31]. Since this analysis is fo-
cused on children under one year of age and during an
emergency with malnutrition and poor hygiene, we de-
creased the proportion of mild diarrhea cases by 20%, from
64.8% to 52%, and increased the proportion of moderate
by 20%, from 34.7% to 42%. We then adjusted severe diar-
rhea cases accordingly, from 0.5% to 6%, to total 100%. To
determine the rate of severe rotavirus diarrhea, severe diar-
rhea was multiplied by the proportion of diarrhea due to
rotavirus (48%) detected through hospital surveillance
among Malawi children under one year of age, since no
Somalia specific data were available and Malawi is the clos-
est comparable country from which data were available
[29,32]. We assumed that rotavirus detection rates de-
creased with decreasing severity of disease by approximately
25% for each severity decrease, as previously described [7].
Mortality
To estimate the rotavirus mortality rate, we assumed
that proportion of diarrheal hospitalizations due to rota-
virus approximates the proportion of diarrheal deaths
due to rotavirus [33,42]. To determine the diarrheal
mortality rate, the total under-one years of age mortality
rate in Somalia (103.72 per 1,000 live births) was multi-
plied by the estimated proportion of all deaths attribut-
able to diarrhea [43]. There are no good estimates for
deaths due to diarrhea in Somalia so we used published
estimates for under-5 years of age in Mali (18.3%) [44].
To determine the rotavirus mortality rate, this rate was
multiplied by the percent of severe diarrhea attributable
to rotavirus among children under one year old (48%)
[29,32]. Therefore, the rotavirus-associated mortality among
those less than one year of age was found to be 9.1 per
1,000 (Table 1).
Healthcare utilization
We assumed the proportion of children who would re-
ceive care would be equivalent to Somalia’s MICS3 report
that 25% of children aged under five years received some
form of oral rehydration therapy for diarrhea [30]. Because
of the large number of IDPs with inadequate access to
health services, especially in the two southern zones [18],
for severity of illness we did not differentiate level, but
only length of care. Among those children receiving care,
based on published reports we assumed children with se-
vere cases of rotavirus would have four days of care and
moderate cases would have two days of care [32,39].
Costs
Cost estimates were obtained from several sources. We
used the Gavi-subsidized vaccine price for the Rotarixvaccine of $0.15 per dose [45]. The operational costs
were estimated by UNICEF at $3.00 per child per
immunization campaign, which was equal to the cost of
measles vaccination per child in Somalia (Heather Papowitz,
personal communication, August 14, 2013). No data were
available for RI costs in Somalia so we assumed it would be
US$0.34 similar to other published reports from African
countries [32,33]. When determining the number of
doses needed for a RI, a wastage rate of 10% was used
[33]. We used standardized WHO-CHOICE (CHOosing
Interventions that are Cost Effective) to estimate the per
diem costs of a health care visit [41]. Somalia estimates
were not available so we used the average of Ethiopia
and Kenya, two neighboring countries where the ma-
jority of Somali refugees seek asylum. The cost of care
was US$1.01 per day. No discounting was taken into
account because the analytic horizon was only one year.
Vaccine program coverage and effectiveness
For SIA base-case estimates and lower and upper limit of
vaccination coverage, we used several data sources for
vaccination coverage following measles supplemental
immunization activities from Darfur, Sudan, Afghanistan,
and refugee camps in Kenya [34-37]. Vaccine coverage for
RI was estimated to be 47%, the median between the 2012
RI coverage of DTP1 (52%) and DTP3 (42%) obtained
from the WHO vaccine-preventable diseases monitoring
system [46].
For both SIA and RI, rotavirus vaccine provides het-
erotypic immunity with better protection against severe
rotavirus disease [33]. Efficacy against severe rotavirus-
associated disease was assumed to be 50% for full-series
based on clinical trial data from Africa [47]. No specific
data of rotavirus efficacy against moderate cases exist
from a country comparable to Somalia; therefore, we
assumed effectiveness against moderate cases of rota-
virus to be 20% lower than the estimated effectiveness
against severe disease [33]. Given that vaccine effect-
iveness against office visits was lower than effective-
ness against hospitalizations in clinical trials in developed
countries, we assumed that vaccine effectiveness against




The costs and benefits of implementing a rotavirus
immunization campaign during a humanitarian emer-
gency were compared to no vaccination using Excel
2010 (Redmond, WA). The model was analyzed under
base case scenario to determine the costs of different op-
tions: no vaccination, full-series of Rotarix vaccine via RI
or full-series of Rotarix vaccine via SIA. A one-way sen-
sitivity analysis was conducted to evaluate the impact
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the main model outcome, incremental cost-effectiveness
ratio.Cost-effectiveness
The main summary measure for the incremental cost-
effectiveness ratio (ICER) was cost per disability-adjusted
life-years (DALY) averted, expressed in 2013 US dollars.
DALYs were estimated using the WHO life expectancy
data with age weighting. The disability weight for severe
diarrhea in children under five years of age from “The
2010 Global Burden of Disease” was used to calculate
years lost due to disability [48], with the mean duration of
diarrhea of three days [33]. The life expectancy tables used
were last produced in 2010 [49]. Survivors of both severe
and moderate infections are not known to have any
long-term disability resulting from infection [32]; there-
fore, the DALYs were almost entirely based on the years of
life lost [50].Sensitivity analysis
Starting from the base case scenario, univariate sensitiv-
ity analyses were carried out to examine the extent to
which the uncertainty in the variables affected our esti-
mates. We conducted sensitivity analyses for vaccination
coverage for both SIA and RI [51]. Vaccine effectiveness
of any oral antigen is dependent on many factors, such
as vaccine potency at time of administration (cold chain
maintenance), presence of diarrhea, nutritional status,
and receipt of vitamin A. Therefore, sensitivity analyses
were performed on this variable as well [52]. HealthcareTable 2 Rotavirus-related events or costs with and without ro
(lower limit, upper limit)
Without
vaccine




Deaths 3,864 2,956 (1,478-4,434) 908 (454–1,362) 2



































– –utilization varies depending on presence of facilities and
mobility of the target population, in part because of
insurgents limiting mobility and access to facilities. In
addition, access to clean water and sanitation can affect
disease burden. Since access to these services is uncer-
tain during a humanitarian emergency, we performed
sensitivity analysis on use of healthcare systems, diar-
rheal disease burden, and rotavirus-associated mortality
rates (Table 1).Additional assumptions
Several additional assumptions were made. First, we as-
sumed that the proportion of diarrhea due to rotavirus
was similar between the general population in develop-
ing countries and the humanitarian emergency-affected
population. Second, baseline rotavirus vaccine coverage
was assumed to be zero. Third, we assumed that all vac-
cinated children were vaccinated at the appropriate age
or age range for SIA and correct time interval between
doses.Results
Disease and economic burden of rotavirus disease in the
absence of vaccination program
In 2012, we estimated that among children less than
1 year of age, rotavirus diarrheal illnesses resulted in
3,864 deaths, 606,917 cases, and 100,961 children receiv-
ing care (Table 2). The total annual cost of the burden
of rotavirus disease described above would be US
$322,618 (Table 2).tavirus vaccine and averted outcomes with vaccination,
reduction With SIA Averted
by vaccine
% reduction






9.6 93,142 (69,857-116,428) 7,819 (5,864-
9,774)
7.7
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For a rotavirus RI, the number of deaths would be re-
duced to 2,956, a 23.5% reduction from no vaccine or
908 deaths averted and would prevent the loss of 109
DALYs per 1000 children. The total number of cases
would be reduced to 499,251, a 17.7% reduction or
107,665 cases averted. The number of children receiving
care would be 81,203, a 19.6% reduction or 19,758 chil-
dren receiving care averted (Table 2). We estimated that
the introduction of a full-series of rotavirus vaccine in a
SIA would potentially decrease the number of deaths to
3,504, a 9.3% reduction from no vaccine or 359 deaths
averted and would prevent the loss of 43 DALYs per
1000 children. The total number of cases would be re-
duced to 564,309, a 7.0% reduction or 42,608 cases
averted. The number of children receiving care would be
93,142, a reduction of 7.7% or 7,819 children receiving
care averted (Table 2).
Introduction of rotavirus into the RI would cost US
$309,458. Healthcare costs would decrease by 19.8% or
US$63,793 to US$258,825 (Table 2). A full-series rota-
virus SIA program would cost US$715,713. Healthcare
costs would decrease by 7.8% or US$25,246 to $297,372
(Table 2).
Cost-effectiveness
The ICER for rotavirus given in a RI was US$5.30 per
DALY averted (Table 3). The base-case scenario ICER
for a full-series SIA strategy was US$37.62 per DALY
averted (Table 3). We also examined cost per case
averted and cost per death averted. A rotavirus RI is US
$2.81 per case averted and US$270.56 per death averted
(Table 3). A full-series SIA strategy is US$16.20 per case
averted and US$1,921.58 per death averted (Table 3).
Sensitivity analysis
Figure 1 shows a tornado analysis of sensitivity. The var-
iables that most affected the ICER for both full-series RI
and SIA of rotavirus vaccine were: (1) vaccine program
costs, (2) rotavirus-associated mortality rate, and (3) vac-
cine effectiveness against death.
For the RI, when program costs varied from US$0.05
to US$1.00 the resulting ICER ranged from US$1.35 to
US$14.28 per DALY averted, respectively (Figure 1).




RI value SIA value
Cost per DALY averted 5.30 (1.35-14.28) 37.62 (12.86-74.93)
Cost per case averted 2.81 (0.58-6.15) 16.20 (5.54-21.54)
Cost per death averted 270.56 (68.85-
729.62)
1,921.52 (656.90-
2,553.83)13.65 per 1,000, the ICER ranged from US$10.54 to US
$3.54 per DALY averted, respectively. When vaccine ef-
fectiveness against death varied from 37.5% to 62.5%, the
resulting ICER ranged from US$7.05 to US$4.24 per
DALY averted, respectively (Figure 1). The net cost
(medical plus vaccine program costs) of a RI strategy
would be between US$385,135 and US$985,104 and
avert up to 1,362 deaths and 134,582 cases (Table 2).
For SIA, when program costs varied from US$1.00 to
US$4.00 the resulting ICER ranged from US$12.86 to
US$50.00 per DALY averted, respectively (Figure 1).
When the mortality rate ranged from 4.55 per 1,000 to
13.65 per 1,000, the ICER ranged from US$74.93 to US
$25.09 per DALY averted for SIA. When vaccine effect-
iveness against death varied from 37.5% to 62.5%, the
resulting ICER for SIA ranged from US$50.07 to US
$30.13 per DALY averted (Figure 1). The resulting net
cost (medical plus vaccine campaign costs) of a SIA strat-
egy would be between US$558,664 and US$1,240,295 and
avert up to 539 deaths and 53,260 cases (Table 2).
Discussion
This analysis found that administering rotavirus vaccine
in a routine immunization strategy would have a greater
health impact and better cost-effectiveness than SIA.
While rotavirus immunization appears to be more cost-
effective if given in a RI it is important to remember that
because of the lack of infrastructure and trained work-
force in Somalia; only about 40% of vaccines adminis-
tered are given within the RI infrastructure (A. Kebede,
WHO-Somalia, personal communication, March 5, 2014).
This lack of infrastructure would probably result in add-
itional costs to RI with the introduction of rotavirus vac-
cine, which were not taken into consideration. Therefore,
the cost-effectiveness of RI may be an over-estimate given
the need for improvements in cold chain and logistics
with the addition of another antigen. This study serves to
show the cost-effectiveness of rotavirus vaccine in both RI
and SIA. When RI does not function during humanitarian
emergencies, SIAs may be conducted to decrease disease
burden and mortality.
According to WHO, a cost-effective intervention is
when the ICER is less than three times the per capita
GDP and very cost-effective intervention when the ICER
is less than one times the per capita GDP (US$112 in
2011) [53,54]. The present study shows that vaccinating
against rotavirus during a humanitarian emergency may
be very cost-effective regardless of the strategy. Rotavirus
vaccination may also be cost-effective in the neighboring
refugee camps of Ethiopia and Kenya, where the major-
ity of Somali refugees fled during the 2011 famine and
subsequently [2], assuming the cost of vaccination and
medical costs are not too much greater. In addition,
while long-term efficacy of a single dose of rotavirus
A RI sensitivity analysis
B SIA sensitivity analysis
0 5 10 15
Vaccine administration costs (US$0.05-1.00)
Mortality rate (4.55-13.65 per 1,000)
Vaccine effectiveness death (37.5-62.5%)
Diarrhea disease burden (15.75-26.25%)
Vaccine effectiveness moderate (30-50%)
Care (18.75-31.25%)
Vaccine effectiveness severe (37.5-62.5%)
Vaccine effectiveness mild (22.5-37.5%)
Vaccine coverage (35.25-58.75%)
Cost per DALY averted
0 20 40 60 80
Mortality rate (4.55-13.65 per 1,000)
Vaccine administration cost (US$1.00-4.00)
Vaccine effectiveness death (37.5-62.5%)
Diarrhea disease burden (15.75-26.25%)
Vaccine effectiveness moderate (30-50%)
Vaccine effectiveness severe (37.5-62.5%)
Care (18.75-31.25%)
Vaccine effectiveness mild (22.5-37.5%)
Vaccine coverage (45-75%)
Cost per DALY averted
Figure 1 Tornado diagrams of univariate sensitivity analysis of rotavirus vaccination campaign. (A) Sensitivity analysis for RI and (B) Sensitivity
analysis for SIA.
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only receive one-dose. A one-dose SIA using 75% vac-
cine coverage, a rate achievable in other SIAs [34-37],
and a vaccine effectiveness of 25% against death and se-
vere disease, 20% against moderate disease, and 15%
against mild/subclinical disease, which is 50% of that of
a full course [33,55] would still reduce morbidity and
mortality and be cost-effective at US$37.62 per DALY
averted. While there are certain scenarios presented
such as low diarrheal disease incidence and low mortal-
ity rate where SIA is no longer cost-effective, the reality
of the situation during a humanitarian emergency makes
these conditions unlikely.
Findings from these analyses agree with findings from
previous cost-effectiveness analysis for rotavirus vaccineintroduction into developing countries, including those
countries that have experienced humanitarian emergen-
cies, such as Uganda, Democratic Republic of Congo,
and Afghanistan, that rotavirus vaccine would be cost-
effective [25,33,50,56,57]. Like other studies, variables
most influencing the ICER in the sensitivity analysis
were program costs and mortality rate [32,33]. Changes
in vaccine coverage did not have a substantial impact on
cost-effectiveness estimates in the sensitivity analysis,
which is similar to other published findings [33,39]. The
high operational costs of SIAs make it substantially more
expensive than if delivered within the RI and greatly de-
creases the cost-effectiveness of the SIA program compared
to the RI. However, if it was given at the time of measles
SIA, this administrative cost could be greatly reduced.
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Study (GEMS) reinforces the finding that rotavirus is a
major cause of moderate to severe diarrhea among chil-
dren less than five years old [6]. Exacerbation of en-
demic rotavirus disease pattern during an emergency
can be due to intense transmission and/or increase in
case-fatality rate as a result of malnutrition, lack of
health infrastructure, and low access to existing health
services [26,58]. For those surviving, these episodes of
diarrhea can also substantially affect physical growth, fur-
ther justifying the use of rotavirus immunization alongside
other diarrhea prevention strategies [59].
According to Moodley, et al., finding affordable mea-
sures, including immunization, to prevent unnecessary
illness and death in a humanitarian emergency is both
beneficial and cost-effective. One of the primary mea-
sures to prevent unnecessary illness and death from
diarrheal diseases in emergency settings is through hy-
giene promotion activities, such as improving hand
washing practices. Although these practices should con-
tinue, in 2005–2006, Somali mothers had poor hand
washing practices; only 45.4% reported washing hands
after cleaning babies bottoms and 34.4% before feeding
babies [30]. Providing an immunization intervention for
a major cause of diarrheal morbidity and mortality
among infants in humanitarian emergencies becomes a
humanitarian consideration in addition to a cost-benefit
consideration. For rotavirus, the WHO/SAGE decision-
making factors for vaccine deployment appear to have
all been met: the disease burden is great, the vaccine-
related risk is low, prevention in this setting is more
feasible than treatment, the vaccine duration is probably
sufficient for the vulnerable period of the child’s life, cost
is reasonable, and herd immunity is possible [60].
Limitations
As with any modeling exercise, the necessary simplifica-
tion of a complex reality implies limitations that must be
considered in applying the results. Since there is almost
no surveillance data to specify the etiology of diarrhea
during a humanitarian emergency, we had to estimate
the rotavirus prevalence. If the true disease incidence is
different than the estimated disease incidence, then the
vaccine may be more or less cost-effective. Studies to
better assess rotavirus disease burden during a humani-
tarian emergency would be beneficial in providing a
more representative picture of the disease incidence.
While we performed sensitivity analysis on the two-week
diarrheal disease burden we assumed the proportion that
would be severe, moderate, and mild would not change
and this may not be reflective of the true proportions.
Post-implementation evaluation and continued surveil-
lance for rotavirus disease will remain critical to define
vaccine impact on disease burden. Furthermore, only aone-year analytic horizon was examined, which did not
take into consideration the additional benefit for the
vaccinated children beyond their first year of life. How-
ever, one study found that only 18% of rotavirus infec-
tions occurred after one year of age [29]. We did not
take into account the effects of herd immunity of rota-
virus vaccination, which may lower disease burden and
further increase benefit of vaccination.
The model also did not consider possible vaccine side
effects, including intussusception that might become ap-
parent with large-scale implementation of the vaccine.
Post-marketing surveillance has identified a small risk of
intussusception associated with the rotavirus vaccine
[61,62]. However, given the probable high burden of
rotavirus disease in humanitarian emergencies, it would
be very unlikely that this risk would significantly alter
the cost-effectiveness of the vaccine. In addition, Patel,
et al. have argued for the removal of the age restriction
of vaccination as they showed the benefit of vaccination
to age three years overweighed the risk of deaths associ-
ated with intussusception [28]. A different distribution
of healthcare seeking behavior than that used in our
models will influence the economic burden and cost-
effectiveness of the vaccination campaign. The range of
vaccine coverage was an estimate and may not be a true
estimate that can be achieved in Somalia during RI or a
SIA.
Conclusions
The ability to illustrate the cost-effectiveness of a rota-
virus vaccination campaign during a humanitarian emer-
gency adds another layer of evidence that such programs
represent good investments. The number of humanitar-
ian emergencies has been on the rise, leading to a record
number of people, particularly children aged under one
year, at risk for infectious diseases [63]. Diarrhea remains
a leading cause of mortality among children in low-
income countries; many of these countries are at risk for
experiencing or have experienced a humanitarian emer-
gency. The reduction of child mortality is one of the
United Nations’ Millennium Development Goals, de-
creasing child mortality during a humanitarian emergency
will aid in reaching this goal. The decision to implement
vaccination against a high-risk disease during an emer-
gency should be made on the basis of epidemiological,
vaccine, political, logistical, and ethical consideration that
are specific to the context of the emergency [26]. By show-
ing that rotavirus vaccination serves to reduce morbidity
and mortality and is cost-effective, may help augment in-
terventions during a humanitarian emergency.
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